치질 치료 기기 시장 : 세계 예측(2026-2032년)

The Hemorrhoid Treatment Devices Market is projected to grow by USD 1,275.26 million at a CAGR of 6.01% by 2032.

Hemorrhoid treatment devices are used to manage symptomatic internal and external hemorrhoids through office-based, ambulatory, and surgical interventions, including rubber band ligation systems, infrared coagulation instruments, bipolar and electrotherapy devices, Doppler-guided hemorrhoidal artery ligation systems, stapling devices, laser platforms, cryotherapy tools, and ancillary anoscopes or proctoscopes. Demand for these devices is supported by well-documented clinical drivers: hemorrhoidal disease is common in adult populations, with prevalence reported across primary care, gastroenterology, and colorectal practice, and risk increases with age, constipation, pregnancy, obesity, prolonged straining, sedentary behavior, and low-fiber diets. Patients and clinicians increasingly seek faster recovery, reduced postoperative pain, lower complication risk, and minimally invasive care pathways. Clinical guidelines from gastroenterology and colorectal surgery societies consistently position conservative therapy as first-line management and recommend office-based procedures, particularly rubber band ligation, for many patients with symptomatic grade I to III internal hemorrhoids, while operative technologies are reserved for advanced, recurrent, prolapsing, or complicated disease. The executive landscape for hemorrhoid treatment devices is therefore shaped by three converging priorities: improved symptom control, reduced procedure-related discomfort, and workflow efficiency for outpatient colorectal, gastroenterology, and surgical practices.

Transformative Shifts in the Hemorrhoid Treatment Device Landscape

The hemorrhoid treatment devices landscape is shifting from hospital-centric excisional surgery toward earlier, less invasive, and more patient-friendly interventions delivered in outpatient departments, ambulatory surgery centers, and office settings. Rubber band ligation remains widely used because it is guideline-supported, comparatively simple, and suitable for a broad portion of internal hemorrhoid cases; however, energy-based and vessel-targeting techniques are gaining clinical attention where providers prioritize hemostasis, precision, and reduced tissue trauma. Stapled hemorrhoidopexy and Doppler-guided hemorrhoidal artery ligation have contributed to the evolution of prolapse-focused treatment strategies, while laser hemorrhoidoplasty and other thermal approaches are being assessed for recovery profile, pain reduction, and suitability in selected patients. At the same time, procurement decisions increasingly depend on sterilization requirements, disposable versus reusable economics, physician training burden, reimbursement compatibility, and evidence quality. Patient expectations are also transforming device adoption as individuals increasingly compare treatment options based on downtime, pain, recurrence risk, complications, and the ability to return quickly to work. These shifts are encouraging device developers and care providers to align product design with outpatient throughput, standardized technique, safety documentation, clinical auditability, and patient-centered outcomes.

Cumulative Impact of Artificial Intelligence on Hemorrhoid Care

Artificial intelligence is beginning to influence the hemorrhoid treatment device ecosystem indirectly through diagnostics, triage, workflow optimization, documentation, and evidence generation rather than replacing procedural judgment. AI-enabled clinical decision support can help stratify patients by symptom severity, bleeding risk, constipation history, anticoagulant use, prior treatment failure, and red-flag features that require colonoscopic evaluation or specialist referral. In endoscopy and imaging-adjacent workflows, computer-aided detection tools are strengthening attention to colorectal pathology, which is important because rectal bleeding attributed to hemorrhoids must be differentiated from other gastrointestinal conditions, including inflammatory bowel disease, fissures, polyps, and malignancy. Natural language processing can improve procedure note standardization, coding accuracy, post-procedure follow-up, adverse event monitoring, and registry-based outcomes research. In device development, machine learning can support design optimization, material testing, usability assessment, complaint trending, and post-market surveillance by identifying patterns in recurrence, pain scores, bleeding control, reintervention, and device-related events. The cumulative impact of AI will be strongest where it improves clinical consistency, reduces administrative friction, and supports real-world evidence for hemorrhoid treatment devices, while maintaining physician oversight, data privacy protections, bias assessment, and transparency in algorithmic recommendations.

Key Regional Insights for Hemorrhoid Treatment Devices

Asia-Pacific is characterized by rising access to specialist care, expanding ambulatory infrastructure, and growing awareness of minimally invasive hemorrhoid procedures in urban centers. China, India, Japan, South Korea, Australia, and Southeast Asian health systems show different adoption pathways, with mature markets emphasizing quality assurance and procedural efficiency and emerging markets prioritizing affordability, training, and broader access to proctology services. North America benefits from established colorectal surgery and gastroenterology networks, strong outpatient procedure capacity, and guideline-based use of office procedures such as rubber band ligation for appropriate internal hemorrhoid grades. The region's adoption environment is influenced by reimbursement structures, malpractice sensitivity, high patient expectations for low-pain treatment, and a preference for evidence-backed technologies. Latin America demonstrates increasing use of minimally invasive and office-based hemorrhoid treatment devices in private healthcare networks and metropolitan hospitals, while public sector adoption is more dependent on procurement budgets, physician training, and availability of reusable or cost-efficient systems. Europe reflects a highly regulated environment where device safety, clinical evidence, conformity assessment, and post-market surveillance are central to adoption, with Western European countries generally showing broader access to advanced colorectal procedures and parts of Eastern Europe emphasizing cost-effectiveness and hospital modernization. In the Middle East, specialist hospital expansion, medical tourism corridors, and investment in advanced surgical infrastructure support the use of modern hemorrhoid treatment devices, particularly in urban tertiary centers. Africa presents a more heterogeneous landscape, with adoption concentrated in private hospitals and major referral centers; broader utilization is linked to colorectal workforce availability, diagnostic access, affordability, referral pathways, and supply-chain reliability.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN countries are advancing hemorrhoid treatment device adoption through expanding private hospital networks, growing ambulatory surgery capacity, and increasing demand for minimally invasive gastrointestinal and colorectal interventions, although adoption varies by healthcare financing, specialist density, and urban-rural access. The GCC shows strong alignment with advanced hospital infrastructure, specialist recruitment, and demand for high-quality, low-downtime procedures, supporting uptake of energy-based, ligation, and surgical hemorrhoid technologies in well-equipped urban facilities. The European Union is shaped by stringent medical device regulation, clinical evidence expectations, and harmonized safety requirements, making documentation, traceability, labeling, and post-market performance essential for suppliers. BRICS economies collectively represent diverse adoption conditions: China and India emphasize scale, affordability, and expanding access; Brazil supports device use through both private and public pathways; Russia's environment is influenced by domestic procurement priorities and healthcare infrastructure distribution; and South Africa's uptake is concentrated in specialist and private care settings. G7 countries typically feature mature regulatory oversight, established colorectal care pathways, advanced ambulatory infrastructure, and high expectations for clinical evidence, which favor devices with documented safety, procedural efficiency, reproducible outcomes, and clinician training support. NATO member countries include varied healthcare systems but commonly prioritize supply-chain resilience, regulatory compliance, hospital readiness, procurement transparency, and standardized clinician training, all of which affect continuity of hemorrhoid treatment device availability.

Key Country Insights for Hemorrhoid Treatment Device Adoption

The United States has a strong outpatient and ambulatory surgery environment for hemorrhoid treatment devices, with clinical practice shaped by colorectal and gastroenterology guidelines, patient demand for rapid recovery, and extensive use of office-based procedures for eligible internal hemorrhoids. Canada reflects a publicly funded healthcare context where access can vary by province, making efficient outpatient interventions valuable for reducing surgical burden while maintaining quality standards. Mexico shows growing adoption in private hospitals and urban specialty clinics, supported by proximity to advanced device supply chains and demand for cost-conscious minimally invasive procedures. Brazil has one of Latin America's more developed specialist care environments, with hemorrhoid device utilization influenced by the contrast between private-sector availability and public-sector procurement constraints. The United Kingdom emphasizes evidence-based clinical pathways, referral efficiency, and appropriate use of procedural interventions, with adoption shaped by national health system priorities and waiting-list pressures. Germany benefits from a highly developed hospital and ambulatory specialist infrastructure, strong surgical training, and rigorous device quality expectations. France, Italy, and Spain demonstrate established colorectal care capabilities, with device selection influenced by reimbursement, physician familiarity, and preference for techniques that balance recurrence control with postoperative comfort. Russia's adoption environment is shaped by regional healthcare disparities, procurement policy, and availability of trained specialists in major urban centers. China is expanding access to proctology and gastrointestinal care through hospital modernization and large urban healthcare networks, while domestic manufacturing capability and cost sensitivity influence purchasing patterns. India shows substantial need for hemorrhoid care due to lifestyle and dietary risk factors, with adoption driven by private hospitals, day-care surgery centers, and demand for faster recovery, while affordability and clinician training remain key determinants. Japan and South Korea combine advanced medical technology environments with strong expectations for precision, safety, and patient comfort, supporting selective adoption of modern ligation, energy-based, and surgical devices. Australia's adoption is supported by specialist colorectal services, private hospital access, and guideline-based care, with geographic distribution influencing access outside major cities.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated product portfolios that address the full continuum of hemorrhoid care, from low-cost office-based ligation systems to advanced energy-based and surgical solutions for complex disease. Device strategies should emphasize evidence generation using patient-reported pain, bleeding resolution, prolapse improvement, recurrence, return-to-activity time, complication rates, reintervention frequency, and long-term follow-up where feasible. Training is a decisive adoption lever: manufacturers and distributors should support standardized procedural education, simulation, proctoring, competency documentation, and clear patient-selection guidance for colorectal surgeons, gastroenterologists, and general surgeons. Commercial teams should adapt portfolios to local purchasing realities by balancing disposable convenience with reusable affordability, particularly in emerging markets. Regulatory teams must maintain strong post-market surveillance, adverse event reporting, sterilization validation, biocompatibility documentation, and usability evidence, especially in regions with tightening device oversight. Digital capabilities should be developed responsibly, including AI-supported documentation, outcomes tracking, inventory planning, and patient follow-up, while protecting sensitive health data. Finally, leaders should strengthen supply-chain resilience for consumables, bands, probes, fibers, stapling components, and sterilization-compatible accessories, because procedure continuity is essential for outpatient productivity and provider trust.

Research Methodology

This executive summary is developed through a structured secondary research approach using publicly available and verifiable sources, including clinical practice guidelines, peer-reviewed medical literature, regulatory frameworks, public health references, hospital procedure standards, and medical device safety documentation. The analysis prioritizes evidence related to hemorrhoidal disease management, minimally invasive proctology, outpatient procedure adoption, device safety, patient outcomes, infection prevention, and regional healthcare infrastructure. Information is synthesized without presenting market sizing, market share, revenue estimates, or forecasts. Regional, group, and country insights are interpreted through healthcare access, regulatory maturity, reimbursement environment, clinician training capacity, ambulatory infrastructure, procurement conditions, and technology adoption patterns. The methodology emphasizes cross-validation of clinical and policy signals, exclusion of unsupported promotional claims, and alignment with recognized standards in evidence-based medicine and medical device evaluation.

Conclusion

Hemorrhoid treatment devices are evolving within a healthcare environment that favors minimally invasive intervention, outpatient efficiency, and patient-centered recovery. Rubber band ligation and other office-based procedures remain central for suitable internal hemorrhoids, while energy-based, Doppler-guided, stapling, and laser technologies continue to shape treatment options for more advanced or selected cases. Adoption depends less on novelty alone and more on clinical evidence, training, safety, reimbursement fit, sterilization practicality, and workflow benefits. Regional differences are substantial, with mature healthcare systems emphasizing evidence and quality control, while emerging markets prioritize affordability, access, and scalable clinician education. Artificial intelligence will increasingly strengthen diagnostic triage, documentation, post-market surveillance, and real-world evidence development, but procedural outcomes will continue to depend on appropriate patient selection and skilled clinical execution. Industry participants that combine validated devices, strong training ecosystems, responsible digital integration, and resilient supply chains will be best positioned to support modern hemorrhoid care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Hemorrhoid Treatment Devices Market, by Product Type

• 7.1. Introduction
• 7.2. Cryotherapy Devices
  • 7.2.1. Gas Compression Based
  • 7.2.2. Liquid Nitrogen Based
• 7.3. Hemorrhoidectomy Devices
  • 7.3.1. Ligasure Devices
  • 7.3.2. Stapler Devices
  • 7.3.3. Traditional Scalpel Instruments
• 7.4. Infrared Coagulation Devices
  • 7.4.1. Contact Infrared Coagulation
  • 7.4.2. Non-Contact Infrared Coagulation
• 7.5. Laser Treatment Devices
  • 7.5.1. CO2 Laser Devices
  • 7.5.2. Diode Laser Devices
  • 7.5.3. Nd:YAG Laser Devices
• 7.6. Rubber Band Ligation Devices
• 7.7. Sclerotherapy Devices
  • 7.7.1. Aethoxysklerol Syringes
  • 7.7.2. Polidocanol Syringes

8. Hemorrhoid Treatment Devices Market, by Payer Type

• 8.1. Introduction
• 8.2. Government Insurance
  • 8.2.1. Medicaid
  • 8.2.2. Medicare
• 8.3. Out-of-Pocket
  • 8.3.1. Assistance Programs
  • 8.3.2. Self-Pay
• 8.4. Private Insurance
  • 8.4.1. Employer-Funded Plans
  • 8.4.2. Individual Plans

9. Hemorrhoid Treatment Devices Market, by End User

• 9.1. Introduction
• 9.2. Ambulatory Surgical Centers
  • 9.2.1. Hospital-Owned ASC
  • 9.2.2. Physician-Owned ASC
• 9.3. Clinics
  • 9.3.1. General Clinics
  • 9.3.2. Proctology Clinics
• 9.4. Home Care Settings
  • 9.4.1. Nurse-Administration
  • 9.4.2. Self-Administration
• 9.5. Hospitals
  • 9.5.1. Private Hospitals
  • 9.5.2. Public Hospitals

10. Hemorrhoid Treatment Devices Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Online
• 10.3. Offline

11. Hemorrhoid Treatment Devices Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Hemorrhoid Treatment Devices Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Hemorrhoid Treatment Devices Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Share Analysis, 2025
• 14.2. FPNV Positioning Matrix, 2025
• 14.3. Market Concentration Analysis, 2025
  • 14.3.1. Concentration Ratio (CR)
  • 14.3.2. Herfindahl Hirschman Index (HHI)
• 14.4. Recent Developments & Impact Analysis, 2025
• 14.5. Product Portfolio Analysis, 2025
• 14.6. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. A.M.I. Agency for Medical Innovations GmbH
• 15.2. B. Braun Melsungen AG
• 15.3. Boston Scientific Corporation
• 15.4. BOWA-electronic GmbH & Co. KG
• 15.5. CONMED Corporation
• 15.6. Cook Medical
• 15.7. Erbe Elektromedizin GmbH
• 15.8. Hologic Inc.
• 15.9. Integra LifeSciences Corporation
• 15.10. Johnson & Johnson
• 15.11. Karl Storz SE & Co. KG
• 15.12. Medline Industries LP
• 15.13. Medtronic plc
• 15.14. Mermaid Medical A/S
• 15.15. Olympus Corporation
• 15.16. Privi Medical
• 15.17. Purple Surgical
• 15.18. Renew Medical Inc.
• 15.19. Richard Wolf GmbH
• 15.20. Sklar Surgical Instruments
• 15.21. Smith & Nephew plc
• 15.22. Teleflex Incorporated